Agilent Technologies Inc. announced it has expanded its
family of sub-2 µm particle
300 Angstrom pore columns for reversed-phase liquid chromatography with ZORBAX
300SB-C3 and 300-Diphenyl 1.8 µm columns.
The columns extend the benefits of reversed-phase
biomolecule separations to ultra-high-performance liquid chromatography
(UHPLC). The C3 phase broadens the selectivity and improves peak shape and
recovery options for larger proteins, including antibodies. The diphenyl phase
offers additional selectivity through pi-pi interactions with aromatic amino
acids in the primary structure.
The 1.8 µm particle size and 300 Angstrom pore size bring
UHPLC efficiency, resolution, and quantitation to reversed-phase protein
separations. Additionally, the columns are stable up to 1200 bar. Agilent's StableBond
technology for the C18, C8, and C3 columns, and the end-capped diphenyl with
Pursuit chemistry, deliver symmetrical peaks—even at low pH—when using
trifluoroacetic or formic acid mobile phase modifiers. Column life is not
compromised.
Agilent Technologies
Inc., www.agilent.com
